Global Epinephrine Market to Surpass USD 5.2 Billion by 2026

Global epinephrine market was valued at USD 2040 million in 2017, and is projected to exhibit a CAGR of 11.0 percent from 2018 – 2026.

Significant number of novel pipeline products to augment the market growth

The manufacturers are focused on developing and commercializing innovative drugs and novel drug delivery systems of therapeutic molecules to improve patient quality of life and to cater the clinical shortcomings of the commercially available products. According to the Mayo Clinic, 2016, more than 200,000 cases of anaphylaxis occur annually in the U.S., indicating the higher number of potential patient pool in the region. Also, the World Allergy Organization, in 2015 estimated that up to two percent of the global population, accounting for 150 million people is expected to experience anaphylaxis during their lifetime.

In July 2018, INSYS Therapeutics, Inc. demonstrated the results of early clinical trial for its investigational epinephrine nasal spray, as a potential needle-free, non-invasive, and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis. The investigators also highlighted the benefits of effective needleless alternative delivery options showing rapid drug absorption. In August 2018, FDA granted Fast Track designation for the epinephrine nasal spray. Furthermore, in April 2018, Aquestive Therapeutics initiated the Phase-1 clinical trials for its complex molecule programs- AQST-108 epinephrine molecule for anaphylaxis, which is administered via sublingual route.

The market players are focused on strengthening strategic collaborations to provide products freely at retail outlets, considering shortages in supply of competitors’ epinephrine auto-injectors. For instance, in September 2018, Walgreens and Kaleo entered into partnership under which AUVI-Q would be available at all pharmacies across the U.S. This step will aid in increasing accessibility of epinephrine auto-injector. Also, in July 2018, Adamis Pharmaceuticals announced that Sandoz, a Novartis division, bought the rights to market its epinephrine device, a pre-filled 0.3 mg-dose syringe called Symjepi in the U.S. market. In 2015, Impax Laboratories, Inc. acquired Tower Holdings, Inc. including subsidiaries Amedra Pharmaceuticals LLC. Amedra is manufacturer of the Adrenaclick (epinephrine injection) auto-injector. – Coherent Market Insights